Independent directory Public ClinicalTrials.gov records United States
Condition Directory

Hypertension clinical trials

Directory of U.S. ClinicalTrials.gov public records for Hypertension. Browse Hypertension recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3906
Shown on this page
12
Current sort
Recently updated
Condition scope
Hypertension
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Hypertension studies are organized in the registry

“Hypertension” searches also surface pulmonary hypertension — a different disease with its own research community — so watch for “pulmonary” in titles when scanning results. The blood-pressure portfolio itself includes a high share of behavioral, dietary, and device studies alongside medication trials.

Terms that often appear in related listings

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Hypertension. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 49–60 of 3,906 matching trials for Hypertension.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Conditions
Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Interventions
Tonlamarsen, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Arvada, Colorado • Homestead, Florida • Port Orange, Florida + 10 more
Conditions
Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 65 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • Jackson, Mississippi
Conditions
Pulmonary Hypertension
Interventions
blood draw, Short Performance Physical Battery, Grip strength test, Six minute walk test, Chest CT scan, Dual-Energy X-ray Absorptiometry Scan, Activity monitoring, 24 hour diet recall, Echocardiogram, Quality of Life Questionnaire (emPHasis 10), International Physical Activity Questionnaire Short Form (IPAQ-SF)
Diagnostic Test · Radiation · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Providence, Rhode Island
Conditions
Hypertension
Interventions
E3 Multidisciplinary Team, E3 Self-Guided Hypertension Education Program
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Conditions
Primary Aldosteronism, Hypertension
Interventions
Eplerenone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions
Placebo, LAM-001
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Hypertension Remote Monitoring Evaluation Redesign

NCT06113458
Conditions
Hypertension
Interventions
Standard and One-time Training, Standard and Practice Facilitation, High-intensity and One-time Training, High-intensity and Practice Facilitation
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
272
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 216 more
Conditions
Hypertension, Overweight, Obesity, Cardiovascular Diseases, Sedentary Behavior, Low Physical Fitness
Interventions
Active older Adults
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years to 95 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Miami, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Glaucoma Screening to Enhance At-Risk Californians' Health

NCT06854198
Conditions
Glaucoma
Interventions
Glaucoma screening with optical coherence tomography (OCT), color fundus photography, and tonometry, Educational Brochure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
3
States / cities
Fremont, California • Oakland, California • San Francisco, California
Conditions
Hypertension, Diabetes, Heart Failure, Ambulatory Difficulty, Mobility Limitation
Interventions
Social Support Gamification
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania

About this Hypertension clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Hypertension as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Hypertension.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Hypertension.